|
2017/10/03 |
PharmR - Cancer-Modulation of Lipid Metabolism and Inflammation Resolution |
Prevete N1, Liotti F2, Amoresano A3, et al. New Perspectives in Cancer: Modulation of Lipid Metabolism and Inflammation Resolution. Pharmacol Res. 2017 Oct 3. pii: S1043-6618(17)31207-0.
|
Inflammation is considered an enabling feature of cancer. Besides the persistence of inflammatory stimuli, also defective mechanisms of resolution can lead to chronic inflammation. Inflammation resolution is an active process controlled by lipidic specialized pro-resolving mediators (SPMs), derived from ω-3 or ω-6 essential polyunsaturated fatty acids (PUFA) through the activity of lipoxygenases (ALOX5 and 15). Thus, a lack or defect in resolution mechanisms may affect cancer development and progression by prolonging inflammation. Components of pro-resolving pathways (PUFA, enzymes, or SPMs) have been reported to modulate various cancer features by affecting both epithelial cells and cancer-associated stroma. Here, we will review the most important mechanisms by which SPMs, ω-3/6 PUFA, and ALOXs affect cancer biology, paying particular attention to their role in the inhibition of inflammation and angiogenesis, two of the most important hallmarks of cancer. The collection of these results may suggest novel perspectives in cancer management based on the modulation of lipid metabolism and the production of SPMs. |
Source:
https://www.ncbi.nlm.nih.gov/pubmed/28986132
|
|